Hepatitis D screening: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(25 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hepatitis D}}
{{Hepatitis D}}
{{CMG}}; {{AE}} {{JM}} {{JS}}
{{CMG}}; {{AE}} {{JS}} {{JM}}
 
==Overview==
==Overview==
The general population, with low risk of [[HBV]] and [[HDV]] infection does not need to be screened. However, individuals known to be [[HBsAg]] positive, with acute or chronic [[hepatitis]], or those [[HBsAg]] negative, but who are [[IgM]] anti-HBc positive, should be screened for [[HDV]]. [[Blood]] products should also be screened in order to avoid [[transmission]] of the virus through [[blood transfusion]]s or [[hemodialysis]].


==Screening==
==Screening==
All patients with current or previous [[IV drug use]] history should be evaluated for [[hepatitis B]]. However, [[screening]] is not recommended in [[asymptomatic]] [[HBsAg]] positive patients. Preventive measures and screening may be applied in:
The following groups of patients should be screened for hepatitis D:
 
*Patients known to be [[HBsAg]] positive, who have acute or chronic hepatitis
*[[HBsAg]] positive patients, who have acute or chronic hepatitis D. The follow-up procedures should be equal, regardless of co-infection status with hepatitis D
*Patients who have acute hepatitis B, who are not [[HBsAg]] positive and who are [[IgM]] anti-HBc positive
*Patients who: have acute hepatitis B, are not [[HBsAg]] positive and who are [[IgM]] anti-HBc positive may be tested for [[HDV]].
*Patients with positive [[HBsAg]] and/or HDV antibody should be alerted not to share items such as razors, eating or drinking utensils.
*Patients without [[immunity]] to the virus should be vaccinated
 
The general population, without risk for [[HBV]] and /or [[HDV]], does not need [[screening]].


{{For|Recommendations for Persons Who Should Be Tested for HBV Infection|Hepatitis B screening}}
The general population, without risk for [[HBV]] and [[HDV]] does not need to be [[screening|screened]].


===Recommendations for HCC Screening: AASLD Practice Guidelines 2009===
Blood products should also be screened for the presence of [[HDV]] and [[HBV]], in order to prevent infection by [[blood transfusion]] and [[hemodialysis]].<ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329  }} </ref>
The following groups should be screened with US examination every 6-12 months: ''(Grade II-2)''<ref name="pmid15229781">{{cite journal |author=Lok AS, McMahon BJ |title=[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines] |journal=[[Romanian Journal of Gastroenterology]] |volume=13 |issue=2 |pages=150–4 |year=2004 |month=June |pmid=15229781 |doi= |url=http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdf |accessdate=2012-02-10}}</ref>
* [[HBV]] carriers at high risk for [[HCC]] such as Asian men over 40 years and Asian women over 50 years of age
* Persons with [[cirrhosis]]
* Persons with a family history of [[HCC]]
* Africans over 20 years of age
* Any carrier over 40 years with persistent or intermittent [[ALT]] elevation and/or high [[HBV]] [[DNA]] level >2,000 IU/mL


For [[HBV]] carriers at high risk for [[HCC]] who are living in areas where US is not readily available, periodic screening with [[AFP]] should be considered. (Grade II-2)}}
For recommendations regarding HBV and HCC screening, refer to [[Hepatitis B screening]]<ref name="pmid15229781">{{cite journal |author=Lok AS, McMahon BJ |title=[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines] |journal=[[Romanian Journal of Gastroenterology]] |volume=13 |issue=2 |pages=150–4 |year=2004 |month=June |pmid=15229781 |doi= |url=http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdf |accessdate=2012-02-10}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Hepatitis|D]]
[[Category:Hepatitis|D]]
[[Category:Viruses]]
[[Category:Viruses]]
[[Category:Disease]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Disease]]
[[Category:Hepatology]]
 
[[Category:Gastroenterology]]
{{WH}}
{{WS}}

Latest revision as of 22:06, 29 July 2020

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D screening

CDC on Hepatitis D screening

Hepatitis D screening in the news

Blogs on Hepatitis D screening

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Overview

The general population, with low risk of HBV and HDV infection does not need to be screened. However, individuals known to be HBsAg positive, with acute or chronic hepatitis, or those HBsAg negative, but who are IgM anti-HBc positive, should be screened for HDV. Blood products should also be screened in order to avoid transmission of the virus through blood transfusions or hemodialysis.

Screening

The following groups of patients should be screened for hepatitis D:

  • Patients known to be HBsAg positive, who have acute or chronic hepatitis
  • Patients who have acute hepatitis B, who are not HBsAg positive and who are IgM anti-HBc positive

The general population, without risk for HBV and HDV does not need to be screened.

Blood products should also be screened for the presence of HDV and HBV, in order to prevent infection by blood transfusion and hemodialysis.[1]

For recommendations regarding HBV and HCC screening, refer to Hepatitis B screening[2]

References

  1. Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
  2. Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter |month= ignored (help)

Template:WH Template:WS